Oncology Venture sells two candidates – receives USD 30 million in milestone payments

Biotech company Oncology Venture divests two of its drug candidates to Norwegian CRO. The deal includes milestone payments that could surpass USD 30 million as well as potential sales royalties. CFO is pleased.

Monday, Oncology Venture published a deal in which it divests drug candidates Liplacis and 2X-111. Photo: Oncology Venture / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles